JP2007510622A5 - - Google Patents

Download PDF

Info

Publication number
JP2007510622A5
JP2007510622A5 JP2006534362A JP2006534362A JP2007510622A5 JP 2007510622 A5 JP2007510622 A5 JP 2007510622A5 JP 2006534362 A JP2006534362 A JP 2006534362A JP 2006534362 A JP2006534362 A JP 2006534362A JP 2007510622 A5 JP2007510622 A5 JP 2007510622A5
Authority
JP
Japan
Prior art keywords
antibody
gene
chain gene
vie
vib
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006534362A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007510622A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/033176 external-priority patent/WO2005034733A2/en
Publication of JP2007510622A publication Critical patent/JP2007510622A/ja
Publication of JP2007510622A5 publication Critical patent/JP2007510622A5/ja
Pending legal-status Critical Current

Links

JP2006534362A 2003-10-08 2004-10-08 B細胞慢性リンパ性白血病の診断及び治療のための方法及び組成物 Pending JP2007510622A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50947303P 2003-10-08 2003-10-08
PCT/US2004/033176 WO2005034733A2 (en) 2003-10-08 2004-10-08 Methods and compositions for diagnosis and treatment of b cell chronic lymphocytic leukemia

Publications (2)

Publication Number Publication Date
JP2007510622A JP2007510622A (ja) 2007-04-26
JP2007510622A5 true JP2007510622A5 (cg-RX-API-DMAC7.html) 2007-11-22

Family

ID=34434984

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006534362A Pending JP2007510622A (ja) 2003-10-08 2004-10-08 B細胞慢性リンパ性白血病の診断及び治療のための方法及び組成物

Country Status (6)

Country Link
US (2) US8119340B2 (cg-RX-API-DMAC7.html)
EP (1) EP1678195A4 (cg-RX-API-DMAC7.html)
JP (1) JP2007510622A (cg-RX-API-DMAC7.html)
AU (1) AU2004279441B2 (cg-RX-API-DMAC7.html)
CA (1) CA2541360A1 (cg-RX-API-DMAC7.html)
WO (1) WO2005034733A2 (cg-RX-API-DMAC7.html)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
CA2541360A1 (en) 2003-10-08 2005-04-21 Bradley T. Messmer Methods and compositions for diagnosis and treatment of b cell chronic lymphocytic leukemia
US20070105165A1 (en) * 2005-11-04 2007-05-10 Charles Goolsby Composite profiles of cell antigens and target signal transduction proteins for analysis and clinical management of hematologic cancers
US7767206B2 (en) * 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
TW200918553A (en) * 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
IL299365A (en) 2010-05-27 2023-02-01 Genmab As Monoclonal antibodies against 2HER
NZ604007A (en) 2010-05-27 2015-03-27 Genmab As Monoclonal antibodies against her2 epitope
EP3957653A1 (en) * 2010-06-02 2022-02-23 Dana Farber Cancer Institute, Inc. Humanized monoclonal antibodies and methods of use
WO2012143524A2 (en) 2011-04-20 2012-10-26 Genmab A/S Bispecific antibodies against her2 and cd3
US9175082B2 (en) 2012-05-31 2015-11-03 Sorrento Therapeutics, Inc. Antigen binding proteins that bind PD-L1
AR091649A1 (es) 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
DE102012212025A1 (de) * 2012-07-10 2014-01-16 Osram Gmbh Leuchtmodul
EP2741084B1 (en) 2012-12-07 2020-01-22 AVA Lifescience GmbH Method of prognosing the clinical course of chronic lymphocytic leukemia (CLL)
JP2016507520A (ja) 2013-01-23 2016-03-10 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 安定化されたb型肝炎コアポリペプチド
RS64268B1 (sr) 2013-09-20 2023-07-31 Bristol Myers Squibb Co Kombinacija anti-lag-3 antitela i anti-pd-1 antitela za lečenje tumora
UA122479C2 (uk) 2014-01-24 2020-11-25 Дана-Фарбер Кенсер Інстітьют, Інк. Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1)
EA201691765A1 (ru) 2014-03-14 2016-12-30 Новартис Аг Молекулы антител против lag-3 и их применения
US9976146B2 (en) * 2014-05-30 2018-05-22 Academia Sinica Aptamer targeting MAGE-A3 peptide and uses thereof
US20180340025A1 (en) 2015-07-29 2018-11-29 Novartis Ag Combination therapies comprising antibody molecules to lag-3
WO2017023859A1 (en) * 2015-07-31 2017-02-09 Memorial Sloan-Kettering Cancer Center Antigen-binding proteins targeting cd56 and uses thereof
US20170073397A1 (en) * 2015-08-24 2017-03-16 Medimmune, Llc MrkA Polypeptides, Antibodies, and Uses Thereof
AU2016319126A1 (en) 2015-09-10 2018-04-19 Affigen, Inc. Sequencing-directed selection of tumor theranostics
CN108495651A (zh) 2015-12-17 2018-09-04 诺华股份有限公司 抗pd-1的抗体分子及其用途
US10836810B2 (en) 2017-02-17 2020-11-17 Mapp Biopharmaceutical, Inc. Monoclonal antibodies and cocktails for treatment of ebola infections
WO2018222718A1 (en) 2017-05-30 2018-12-06 Bristol-Myers Squibb Company Treatment of lag-3 positive tumors
JP7301002B2 (ja) 2017-05-30 2023-06-30 ブリストル-マイヤーズ スクイブ カンパニー 抗lag-3抗体または抗lag-3抗体および抗pd-1もしくは抗pd-l1抗体を含む組成物
CN109752548B (zh) * 2019-02-01 2022-05-06 广州金域医学检验中心有限公司 评估慢性淋巴细胞白血病预后的组合试剂及系统
US12378321B2 (en) 2019-03-08 2025-08-05 Memorial Sloan Kettering Cancer Center ADAM17 binding molecules and uses thereof
EP4013794A4 (en) 2019-08-12 2023-11-22 City of Hope ANTI-IL1RAP ANTIBODIES
CA3196496A1 (en) 2020-10-23 2022-04-28 Laurence David TOMS Lag-3 antagonist therapy for lung cancer
EP4341289A1 (en) * 2021-05-18 2024-03-27 Christian-Albrechts-Universität zu Kiel Co-stimulatory multispecific antibodies
CN113461818B (zh) * 2021-06-30 2022-01-21 徐州医科大学 靶向CD276的全人源抗体scFv、嵌合抗原受体、工程化免疫细胞及其制备方法
AU2023231622A1 (en) * 2022-03-07 2024-09-26 Agenus Inc. Anti-ilt2 antibodies and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP2270049A3 (en) * 2002-04-12 2011-03-09 Medimmune, Inc. Recombinant anti-interleukin-9-antibody
CA2541360A1 (en) 2003-10-08 2005-04-21 Bradley T. Messmer Methods and compositions for diagnosis and treatment of b cell chronic lymphocytic leukemia

Similar Documents

Publication Publication Date Title
Grisaru-Tal et al. Metastasis-entrained eosinophils enhance lymphocyte-mediated antitumor immunity
Ghia et al. Ordering of human bone marrow B lymphocyte precursors by single-cell polymerase chain reaction analyses of the rearrangement status of the immunoglobulin H and L chain gene loci
Ghia et al. Chronic lymphocytic leukemia
Keerthivasan et al. β-Catenin promotes colitis and colon cancer through imprinting of proinflammatory properties in T cells
Milstein et al. Monoclonal antibodies and cell surface antigens
Safarzadeh Kozani et al. In like a lamb; out like a lion: marching CAR T cells toward enhanced efficacy in B-ALL
Tjandra et al. Progressive development of a Th1‐type hepatic cytokine profile in rats with experimental cholangitis
JP2009539841A5 (cg-RX-API-DMAC7.html)
CN111148514A (zh) 与免疫调节剂联合应用于癌症免疫治疗的rar选择性激动剂
JP2007510622A (ja) B細胞慢性リンパ性白血病の診断及び治療のための方法及び組成物
Freria et al. Serial systemic injections of endotoxin (LPS) elicit neuroprotective spinal cord microglia through IL-1-dependent cross talk with endothelial cells
Iwata et al. Egr2 drives the differentiation of Ly6Chi monocytes into fibrosis-promoting macrophages in metabolic dysfunction-associated steatohepatitis in mice
JP2008508858A5 (cg-RX-API-DMAC7.html)
Xiang et al. ROS-activated CXCR2+ neutrophils recruited by CXCL1 delay denervated skeletal muscle atrophy and undergo P53-mediated apoptosis
Herberman Mechanisms of cytotoxicity by NK cells
JP2018522061A5 (cg-RX-API-DMAC7.html)
JP2021535100A (ja) M2マクロファージ極性化を調節する方法及び治療におけるその使用
Atherton et al. Bite-size introduction to canine hematologic malignancies
Guo et al. GPR116 receptor regulates the antitumor function of NK cells via Gαq/HIF1α/NF-κB signaling pathway as a potential immune checkpoint
Ikezumi et al. The role of lymphocytes in the experimental progressive glomerulonephritis
JP2008538173A5 (cg-RX-API-DMAC7.html)
Demireva et al. Creation of the 5-hydroxytryptamine receptor 7 knockout rat as a tool for cardiovascular research
JP2008522162A5 (cg-RX-API-DMAC7.html)
Feeney et al. Terminal deoxynucleotidyl transferase deficiency decreases autoimmune disease in MRL-Fas lpr mice
Dang et al. Cutting edge: regulation of uterine NKT cells by a fetal class I molecule other than CD1